Nanodrug Delivery Systems: A Promising Technology for Detection, Diagnosis, and Treatment of Cancer

被引:111
作者
Babu, Anish [1 ,3 ]
Templeton, Amanda K. [1 ,3 ]
Munshi, Anupama [2 ,3 ]
Ramesh, Rajagopal [1 ,3 ,4 ]
机构
[1] Univ Oklahoma, Hlth Sci Ctr, Dept Pathol, Oklahoma City, OK 73104 USA
[2] Univ Oklahoma, Hlth Sci Ctr, Dept Radiat Oncol, Oklahoma City, OK 73104 USA
[3] Univ Oklahoma, Hlth Sci Ctr, Peggy & Charles Stephenson Canc Ctr, Oklahoma City, OK 73104 USA
[4] Univ Oklahoma, Hlth Sci Ctr, Grad Program Biomed Sci, Oklahoma City, OK 73104 USA
基金
美国国家卫生研究院;
关键词
cancer therapy; liposome; nanodrug delivery systems; nanomedicine; polymer nanoparticles; PH-SENSITIVE LIPOSOMES; RESPONSIVE DRUG-DELIVERY; IRON-OXIDE NANOPARTICLES; TARGETED DELIVERY; POLYMERIC NANOPARTICLES; CATIONIC LIPOSOMES; ANTITUMOR-ACTIVITY; PEG NANOPARTICLES; CELLULAR UPTAKE; GENE DELIVERY;
D O I
10.1208/s12249-014-0089-8
中图分类号
R9 [药学];
学科分类号
100702 [药剂学];
摘要
Nanotechnology has enabled the development of novel therapeutic and diagnostic strategies, such as advances in targeted drug delivery systems, versatile molecular imaging modalities, stimulus responsive components for fabrication, and potential theranostic agents in cancer therapy. Nanoparticle modifications such as conjugation with polyethylene glycol have been used to increase the duration of nanoparticles in blood circulation and reduce renal clearance rates. Such modifications to nanoparticle fabrication are the initial steps toward clinical translation of nanoparticles. Additionally, the development of targeted drug delivery systems has substantially contributed to the therapeutic efficacy of anti-cancer drugs and cancer gene therapies compared with nontargeted conventional delivery systems. Although multifunctional nanoparticles offer numerous advantages, their complex nature imparts challenges in reproducibility and concerns of toxicity. A thorough understanding of the biological behavior of nanoparticle systems is strongly warranted prior to testing such systems in a clinical setting. Translation of novel nanodrug delivery systems from the bench to the bedside will require a collective approach. The present review focuses on recent research efforts citing relevant examples of advanced nanodrug delivery and imaging systems developed for cancer therapy. Additionally, this review highlights the newest technologies such as microfluidics and biomimetics that can aid in the development and speedy translation of nanodrug delivery systems to the clinic.
引用
收藏
页码:709 / 721
页数:13
相关论文
共 112 条
[1]
Proapoptotic Peptide-Mediated Cancer Therapy Targeted to Cell Surface p32 [J].
Agemy, Lilach ;
Kotamraju, Venkata R. ;
Friedmann-Morvinski, Dinorah ;
Sharma, Shweta ;
Sugahara, Kazuki N. ;
Ruoslahti, Erkki .
MOLECULAR THERAPY, 2013, 21 (12) :2195-2204
[2]
Targeted nanoparticle enhanced proapoptotic peptide as potential therapy for glioblastoma [J].
Agemy, Lilach ;
Friedmann-Morvinski, Dinorah ;
Kotamraju, Venkata Ramana ;
Roth, Lise ;
Sugahara, Kazuki N. ;
Girard, Olivier M. ;
Mattrey, Robert F. ;
Verma, Inder M. ;
Ruoslahti, Erkki .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2011, 108 (42) :17450-17455
[3]
AHMAD I, 1992, CANCER RES, V52, P4817
[4]
Liposomes: From a Clinically Established Drug Delivery System to a Nanoparticle Platform for Theranostic Nanomedicine [J].
Al-Jamal, Wafa' T. ;
Kostarelos, Kostas .
ACCOUNTS OF CHEMICAL RESEARCH, 2011, 44 (10) :1094-1104
[5]
HER-2-Targeted Nanoparticle-Affibody Bioconjugates for Cancer Therapy [J].
Alexis, Frank ;
Basto, Pamela ;
Levy-Nissenbaum, Etgar ;
Radovic-Moreno, Aleksandar F. ;
Zhang, Liangfang ;
Pridgen, Eric ;
Wang, Andrew Z. ;
Marein, Shawn L. ;
Westerhof, Katrina ;
Molnar, Linda K. ;
Farokhzad, Omid C. .
CHEMMEDCHEM, 2008, 3 (12) :1839-1843
[6]
Liposomal drug delivery systems: From concept to clinical applications [J].
Allen, Theresa M. ;
Cullis, Pieter R. .
ADVANCED DRUG DELIVERY REVIEWS, 2013, 65 (01) :36-48
[7]
Anti-CD19-targeted liposomal doxorubicin improves the therapeutic efficacy in murine B-cell lymphoma and ameliorates the toxicity of liposomes with varying drug release rates [J].
Allen, TM ;
Mumbengegwi, DR ;
Charrois, GJR .
CLINICAL CANCER RESEARCH, 2005, 11 (09) :3567-3573
[8]
Pegylated liposomal doxorubicin HCL (PLD; Caelyx/Doxil®):: Experience with long-term maintenance in responding patients with recurrent epithelial ovarian cancer [J].
Andreopoulou, E. ;
Gaiotti, D. ;
Kim, E. ;
Downey, A. ;
Mirchandani, D. ;
Hamilton, A. ;
Jacobs, Allan ;
Curtin, John ;
Muggia, F. .
ANNALS OF ONCOLOGY, 2007, 18 (04) :716-721
[9]
AS1411 aptamer tagged PLGA-lecithin-PEG nanoparticles for tumor cell targeting and drug delivery [J].
Aravind, Athulya ;
Jeyamohan, Prashanti ;
Nair, Remya ;
Veeranarayanan, Srivani ;
Nagaoka, Yutaka ;
Yoshida, Yasuhiko ;
Maekawa, Toru ;
Kumar, D. Sakthi .
BIOTECHNOLOGY AND BIOENGINEERING, 2012, 109 (11) :2920-2931
[10]
Poly(styrene-co-maleic acid)-based pH-sensitive liposomes mediate cytosolic delivery of drugs for enhanced cancer chemotherapy [J].
Banerjee, Shubhadeep ;
Sen, Kacoli ;
Pal, Tapan K. ;
Guha, Sujoy K. .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2012, 436 (1-2) :786-797